Summary
Want to know what’s new in Hidradenitis Suppurativa Treatments?
Here is our December – March quarter review of clinical research news in HS treatment. We’ve reviewed the news and put it into short blurbs with links provided.
First quarter of 2024 was a fairly good time for HS research. Overall we see several novel treatments preforming fairly well in the first quarter of 2024 for HS. Nothing yet approved for treatment, but we are thinking positive! We might see some significant changes in how HS treatment outcomes are soon. There wasn’t too much news that wasn’t just an update on these other drugs.
**Dec 26th, 2023**
Up-to-$2B Sanofi Collaboration Pays Off for Kymera
Kymera has been testing a first in class protein degrader called KT-474/SAR444656. First in class means the medication uses a unique mechanism of action, or, said another way, we’ve never tried this before! KT-474/SAR444656 targets a protein responsible for inflammatory responses in the body. The drug is being evaluated for use in Atopic Dermatitis (Eczema) and in Hidradenitis Suppurativa. Zen, which is the phase II trial for KT-474/SAR444656 in treating HS, is expected to end early in 2025. The first study testing the drug for H.S. and Eczema went well, so add another option to the pipeline.
– [Link]
In phase 3 trials for Bimekizumab it was shown that patients with severe HS moved towards moderate HS more often than those who were given the placebo. You might even say it’s somewhat effective. The article cautions that efficacy has not been proven and the drug has not been approved by any regulatory bodies yet, but it looks like it has some effect on reducing the severity of HS. It’s the first treatment for HS that targets these two specific immune system pathways at the same time.
– [Link]
This one can be summarized nicely with quotes, “AbbVie has reported positive data from its Phase II clinical trial of the investigational drug lutikizumab (ABT-981).”, “According to the findings, subjects who received 300mg of lutikizumab weekly or every other week demonstrated significantly higher response rates in achieving HiSCR 50 than those on placebo, meeting the primary endpoint.” Which really just means, it was pretty effective. The important thing to keep in mind is that every new drug, even if it’s not a wonder drug, offers a different option. Sometimes it takes more than 8 different drugs to find the one that works for an individual, so more options is good news for those who don’t respond to treatments currently on the market.
– [Link]
“Trivalent camelid nanobody”, the technical term for a new drug going into Phase III trials for treatment of HS. Sonelokimab has received positive feedback from the FDA.
– [Link]
In a continuation of the story on bimekizumab, the company reported an analysis on phase III studies. About 6 of 10 volunteers in the study said they would rate their skin pain as “much better” following the use of the drug. An excerpt here defines their findings on the reduction of pain “Highlights of the BIMZELX data in moderate-to-severe HS presented at AAD 2024:
Impact on pain:
- At Week 48, HSSQ skin pain response was achieved by 64.6–75.7 percent of patients.1*
- At Week 48, HSSQ skin pain score of 0 was achieved by 12.7–19.8 percent of patients.1*
- From Weeks 0–48, HSSQ skin pain scores reduced by 36.9–43.7 percent across treatment groups.1±
- At Week 48, 55.9–63.7 percent of patients rated their skin pain “much better” using the PGI-C-SP.1*
- At Week 48, 3.9–7.8 percent rated PGI-S-SP “severe” vs. 28.5-33.3 percent at baseline and 45.6–47.4 rated PGI-S-SP “mild” vs. 15.1–16.7 percent at baseline.1″
– [Link]
Demonstrating a significantly greater reduction in abscess and inflammatory nodule count in patients with Hurley Stage I and II HS, Ruxotilinib’s data was presented today. “The results presented today reinforce the efficacy and safety profile of ruxolitinib cream, which shows great potential for people living with milder HS,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
In Phase II findings for Lutikizumad, a molecule which alters a unique combination of immune signal pathways, it was shown that it had good results in treating HS.
– [Link]
